Skip to main content
Publications
Kovesdy CP, Ebert N, Vizcaya D, Walsh M, Kosiborod MN, Layton JB, Ziemiecki R, Johannes CB, Pladevall-Vila M, Gee PO, Jefferson N, Chicoye A, Lopes M, Thapa BB, Curhan G, Rangel L, Bhartia M, Liu F, Farjat AE, Oberprieler NG. Change in urine albumin-creatinine ratio and occurrence of hyperkalemia in patients initiating finerenone in the United States: a cohort study from the FOUNTAIN platform. Nephron. 2025 Feb 27;1-26. doi: 10.1159/000543923
Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez-Salas N, Martin-Richard M, Alonso-Orduna V, Vera R, Gallegeo J, Capdevila J, Salud A, Nogue M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X. Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol. 2019 Aug 29;5(11):1566-73. doi: 10.1001/jamaoncol.2019.2294
Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, Copeland G, Meyer RE, Brown AL, Chambers TM, Sok P, Danysh HE, Carozza SE, Sisoudiya SD, Hilsenbeck SG, Janitz AE, Oster ME, Scheuerle AE, Schiffman JD, Luo C, Mian A, Mueller BA, Huff CD, Rasmussen SA, Scheurer ME, Plon SE. Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births. JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1215